NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

LC,



Thanks for reposting your opinions about PFS again, but I think you’re just throwing random mud. Actual PFS was subsequently proven by the OS data, but the predictive PFS data were contaminated and therefore the investigators could not use the predictive PFS data as a reliable surrogate predictor of OS. Instead, they had to wait for actual OS data.

Oncologists always attempt to measure and predict PFS as they should. Every cancer trial investigator will seek to predict PFS in advance of OS which of course takes longer to discover and confirm.

OS is the ultimate standard, but you cannot wait until death to begin evaluating whether a cancer drug is efficacious. The physician must evaluate a patient’s response and try to determine whether the treatment is helping.

Today, doctors have better methods for measuring progression, particularly when studying immunotherapy agents which are still relatively new as the emerging field of cell-based science is leading to rapid changes in the understanding of how cancer can be assessed and treated.

The P3 for the DCVax-L cell-based technology spanned many years. If the trial were designed and commenced in 2023, the investigators would appropriately attempt to measure progression and predict survival using the best methods and most current medical knowledge available in 2023, as any cancer researcher would.



Don’t forget to follow the combo trial! This study has a placebo design and revised methods for attempting to identify progression. More importantly, the interim survival data are brilliant!
https://clinicaltrials.gov/study/NCT04201873



Amid all of the misinformation and bad-faith disinformation pollution online, it is crucial that we refocus our attention beyond baseless social media posts to seek full-context credible sources and consult licensed oncologists…

JAMA Oncology is a peer-reviewed medical journal that us part of the Journal of the American Medical Association (JAMA) network, which is one of the most widely respected and influential medical journal publishers globally.

Being a peer-reviewed journal means that research articles submitted to JAMA Oncology undergo a thorough evaluation process by independent experts in the field before they are accepted for publication. This process helps ensure the quality, validity, and scientific rigor of the research presented in the journal.

Researchers, healthcare professionals, and the medical community rely on publications like JAMA Oncology for up-to-date and credible information in the field of oncology.

For a reliable appraisal of the DCVax-L P3 trial, its design, and the significance of the resulting survival data, it is advisable to refer to the analyses of qualified physicians. One such analysis can be found on the JAMA Oncology website where the link to the independent peer review and supplementary materials are published.

https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/

This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt

— JAMA Oncology (@JAMAOnc) February 15, 2023

https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html

https://www.jci.org/articles/view/169314

https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers

https://hotb.org/wp-content/uploads/2022/05/spore-article-for-donors-4.18.22.pdf

https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials

Our team just met with the @NorthwestBio team to learn about #DCVax and had the pleasure of speaking with longterm DCVax patients. An honor and a privilege. #endbraincancer #sno2023 pic.twitter.com/dw3X76DBru

— EndBrainCancer Initiative (@EndBrainCancer) November 19, 2023